6-[(1,4-Naphthoquinone-2-yl)methyl]thio–Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer

The Warburg effect is a shift from oxidative phosphorylation to anaerobic glycolysis, accompanied by an enormous increase in glucose uptake into cancer cells. We have utilized this effect to design a new group of targeted 1,4-naphthoquinone-glucose derivatives conjugated with a novel thiomethylene linker that are cytotoxic to prostate cancer cells. Compound PeS-9 revealed the highest efficacy and selectivity, which was conditioned by a GLUT-1-mediated uptake. PeS-9 induced androgen receptor degradation followed by downregulation of its signaling. In addition, it increased reactive oxygen species production and induced DNA double-strand breaks. Combinational therapy with PARP inhibitor olaparib resulted in synergistic effects in homologous recombination-deficient cells. The underlying mode of PeS-9's cytotoxic action involved mitochondrial targeting, leading to a loss of mitochondrial membrane potential, release of cytochrome C and apoptosis-inducing factor, activation of caspases-3 and -9, PARP cleavage, and apoptotic cell death. This process was stipulated by downregulation of several antiapoptotic factors and induction of endoplasmic reticulum stress. Moreover, drug-induced activation of signaling pathway mediated by p38, JNK1/2, and ERK1/2 kinases was identified as an important factor of the cytotoxic activity. The anticancer activity of PeS-9 could be confirmed ex vivo using patient-derived tumoroids as well as in vivo in xenografts, demonstrating suppression of tumor growth and decreased dissemination of prostate cancer cells to the lungs. No serious side effects were observed in animal models. This unique combination of anticancer properties makes PeS-9 an attractive candidate for targeted monotherapy against GLUT-1-overexpressing tumors and as a potential combination partner, especially with PARP inhibitors.

Authors

Institutions

Publication Details

Journal
Molecular Cancer Therapeutics
Published
2025-04-29
DOI
https://doi.org/10.1158/1535-7163.mct-24-0955
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

6-[(1,4-Naphthoquinone-2-yl)methyl]thio–Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer

Dmitry N. Pelageev, В. Ф. Ануфриев, Wael Mansour, Christoph Krisp et al.
1 links
Molecular Cancer Therapeutics
PARP inhibition in cancer therapy
article

6-[(1,4-Naphthoquinone-2-yl)methyl]thio–Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer

Dmitry N. Pelageev, В. Ф. Ануфриев, Wael Mansour, Christoph Krisp, Nadja Strewinsky, Maria Riedner, Yuri E. Sabutski, Alexandra Zielinski, Markus Graefen, Malte Kriegs, Mohamed E. Elsesy, Svetlana M. Kovach, Simone Venz, Derya Tilki, Jessica Hauschild, Hartmut Schlüter, Gunhild von Amsberg, Thomas Mair, Tobias Busenbender, Carsten Bokemeyer, Sergey A. Dyshlovoy, Ayham Moustafa, Ksenia L. Borisova, Ekaterina A. Khmelevskaya, Moritz Kaune, Lukas Boeckelmann, Konstantin Hoffer
article en

Abstract

The Warburg effect is a shift from oxidative phosphorylation to anaerobic glycolysis, accompanied by an enormous increase in glucose uptake into cancer cells. We have utilized this effect to design a new group of targeted 1,4-naphthoquinone-glucose derivatives conjugated with a novel thiomethylene linker that are cytotoxic to prostate cancer cells. Compound PeS-9 revealed the highest efficacy and selectivity, which was conditioned by a GLUT-1-mediated uptake. PeS-9 induced androgen receptor degradation followed by downregulation of its signaling. In addition, it increased reactive oxygen species production and induced DNA double-strand breaks. Combinational therapy with PARP inhibitor olaparib resulted in synergistic effects in homologous recombination-deficient cells. The underlying mode of PeS-9's cytotoxic action involved mitochondrial targeting, leading to a loss of mitochondrial membrane potential, release of cytochrome C and apoptosis-inducing factor, activation of caspases-3 and -9, PARP cleavage, and apoptotic cell death. This process was stipulated by downregulation of several antiapoptotic factors and induction of endoplasmic reticulum stress. Moreover, drug-induced activation of signaling pathway mediated by p38, JNK1/2, and ERK1/2 kinases was identified as an important factor of the cytotoxic activity. The anticancer activity of PeS-9 could be confirmed ex vivo using patient-derived tumoroids as well as in vivo in xenografts, demonstrating suppression of tumor growth and decreased dissemination of prostate cancer cells to the lungs. No serious side effects were observed in animal models. This unique combination of anticancer properties makes PeS-9 an attractive candidate for targeted monotherapy against GLUT-1-overexpressing tumors and as a potential combination partner, especially with PARP inhibitors.

Molecular Cancer TherapeuticsVol. 24(9)
Koç University (TR), Universität Hamburg (DE), St Petersburg University (RU), Far Eastern Federal University (RU), Universitätsmedizin Greifswald (DE), Universität Greifswald (DE), University Medical Center Hamburg-Eppendorf (DE), Martini-Klinik (DE), Pacific Institute of Bioorganic Chemistry. GB Elyakova Far Eastern Branch of the Russian Academy of Sciences (RU), University Cancer Center Hamburg (DE), Children Cancer Hospital (EG), HAW Hamburg (DE)
Good health and well-being
Openalex Percentile: Top 86%
PARP inhibition in cancer therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.